Download Files:
Dasatinib
$66 – $118
Products Details
Product Description
– Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively[1]. Dasatinib also induces apoptosis and autophagy.
Web ID
– HY-10181
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C22H26ClN7O2S
Citations
– ACS Omega. October 26, 2022.|ACS Pharmacol Transl Sci. 2023 May 2.|Adv Funct Mater. 27 January 2022.|Aging. 2020 Jun 25;12(12):11337-11348.|Artif Cells Nanomed Biotechnol. 2023 Oct 5.|Behav Brain Res. 2022 Dec 16;114260.|Biochem Pharmacol. 2023 Jan 30.|Bioconjug Chem. 2023 Jul 17.|Biogerontology. 2022 Apr 25:1-15.|Biol Pharm Bull. 2017;40(10):1747-1753. |Biomaterials. 16 September 2022.|Biomed Chromatogr. 2019 Dec;33(12):e4674.|Biomed Pharmacother. 2023 Apr 12;162:114680.|Biomolecules. 2022 Jun 11;12(6):819.|Br J Cancer. 2022 Nov 1.|Breast Cancer Res Treat. 2020 Jan;179(2):337-347.|Cancer Cell Int. 2021 Jun 5;21(1):291.|Cancers (Basel). 2022 Mar 11;14(6):1451.|Cell Biochem Funct. 2020 Jul;38(5):642-650.|Cell Death Dis. 2021 Dec 3;12(12):1126.|Cell Mol Gastroenterol Hepatol. 2022 Apr 2;14(1):75-99.|Cell. 2021 Oct 28;184(22):5670-5685.e23.|Chem Biol Interact. 2021 Oct 27;109729.|Chem Pharm Bull (Tokyo). 2017 Aug 1;65(8):768-775.|Clin Sci. 2021 Jul 20;CS20210571.|Diseases. 2023 Oct 23;11(4):147.|Eur J Pharmacol. 2021 Feb 10;173944.|Exp Cell Res. 2020 Aug 1;393(1):112054.|Exp Eye Res. 2022 Aug 2;223:109207.|Front Cell Dev Biol. 2021 Mar 16;9:618045.|Front Microbiol. 2019 Aug 7;10:1816.|Front Pharmacol. 2021 Mar 8;12:644342.|Harvard Medical School LINCS LIBRARY|Hum Exp Toxicol. 2023 Jan-Dec;42:9603271231188492.|Int J Rheum Dis. 2023 Feb 21.|iScience. 2023 Jul 21.|J Anim Sci Biotechnol. 2021 May 10;12(1):63.|J Cancer Res Clin Oncol. 2022 Nov 19.|J Clin Invest. 2019 Mar 1;129(3):972-987.|J Clin Invest. 2023 Feb 16;e162324.|J Hematol Oncol. 2022 Apr 29;15(1):46.|J Immunol Res. 2022 Apr 28;2022:6324326.|J Immunother Cancer. 2020 Mar;8(1):e000111. |J Med Chem. 2021 Mar 11;64(5):2725-2738.|J Med Chem. 2021 Sep 21.|J Pharm Anal. 2021 Jun 19.|J Pineal Res. 2019 Sep;67(2):e12588. |J Transl Med. 2022 Jun 21;20(1):278.|Kawasaki Medical Journal. 43(2)：63-78，2017.|Leukemia. 2012 Oct;26(10):2233-44.|Leukemia. 2020 Jun;34(6):1524-1539. |Med Oncol. 2022 Dec 16;40(1):49.|Mol Ther. 2023 Feb 28;S1525-0016(23)00116-8.|Molecules. 2018 Mar 23;23(4). pii: E736.|Nat Biomed Eng. 2018 Aug;2(8):578-588.|Nat Cell Biol. 2023 Mar;25(3):493-507.|Nat Commun. 2020 Apr 14;11(1):1790.|Nat Commun. 2020 Apr 20;11(1):1913. |Oncogenesis. 2022 Apr 11;11(1):15.|Oncotarget. 2016 Aug 30;7(35):56241-56252. |Patent. US10174018B2.|Patent. US20180099959A1.|Patent. US20180099960A1.|Patent. US20180099961A1.|Patent. US20180263995A1.|PLoS One. 2013;8(2):e56473.|PLoS One. 2018 Jun 14;13(6):e0199208.|Purdue University. Department of Chemistry.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Stem Cell Reports. 2017 Dec 12;9(6):1948-1960.|Target Oncol. 2020 Oct;15(5):659-671.|Technical University of Munich. 24.01.2018.|Front Pharmacol. 2023 Aug 29;14:1250383.|J Hematol Oncol. 2018 Aug 29;11(1):109. |PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. |Int J Pharm Res Allied Sci. 2023 Mar;13(1):139-148.
References
– [1]Lombardo LJ, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004 Dec 30;47(27):6658-61.
CAS Number
– 302962-49-8
Molecular Weight
– 488.01
Compound Purity
– 99.85
SMILES
– O=C(C1=CN=C(S1)NC2=NC(C)=NC(N3CCN(CC3)CCO)=C2)NC4=C(C=CC=C4Cl)C
Clinical Information
– Launched
Research Area
– Cancer
Solubility
– DMSO : 250 mg/mL (ultrasonic)
Target
– Apoptosis;Autophagy;Bcr-Abl;Src
Isoform
– Bcr-Abl
Pathway
– Apoptosis;Autophagy;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
